New Releases

Premium

Ipsogen this week launched of a new line of assays that enable the standardization of quantitative analysis of BCR-ABL Mbcr by calibrating the results on the International Scale.

Ipsogen said that its BCR-ABL Mbcr IS-MMR DX and BCR-ABL Mbcr IS-MMR kits have CE-marking and are already available in Europe and other non-US markets. Research-use-only kits are planned for launch in North America next year.

Standardization of the analysis of BCR-ABL transcripts is increasingly viewed as medically necessary when administering drugs like Gleevec.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.